ERBB2 and breast cancer: BM occurs in 30–55% of patients with HER2+ metastatic BC, and up to half die from intracranial progression, whereas the median survival rate is only six months in triple-negative BC (TNBC) with BM (Lin et al., 2008; Dawood et al., 2009).